Return to Trial Database

HCRN-GU15-223

Randomized Phase II trial comparing sequential first-line sunitinib and second-line avelumab versus first-line avelumab and second-line sunitinib for metastatic renal cell carcinoma: SUAVE trial: HCRN GU15-223

Status

Study Completed

Cancer Type(s)

Study Contact

Trial Locations

All sites in which the trial HCRN-GU15-223 being conducted in.

No data was found